alimerasciences.com (ALIM) Amount of Cash per Share

Alimera Sciences, Inc. - graphic logo of issuer ALIM

Is it worth investing in Alimera Sciences (ALIM), given the profit dependence on sales of retinal edema treatments and market competition? The calculated cash per share confirms the company's resilience, while the 0.20 value serves as a baseline liquidity indicator. This is supported by the use of proprietary Iluvien implants, which create a stable sales channel. Ultimately, the integration of this therapy into ophthalmological practice ensures long-term vision preservation for patients.

alimerasciences.com (ALIM): Cash per Single Share from 07/04/2022 to 09/21/2024

Comprehensive metric breakdowns and analytics for alimerasciences.com (ALIM)

- market price and analyst price targets:
- cash availability and cash flow indicators:
Summary company analysis:Alimera Sciences
Manufactured product of Alimera Sciences

Cash per share determines the portion of liquid assets attributable to a single security, allowing for an assessment of the business's real intrinsic value. Monitoring this metric protects the investor from management errors and unjustified price inflation. By analyzing the trend of the cash cushion per share, one can identify insolvency risks. For Alimera Sciences (ALIM), this reserve is critical in the event of losing sales markets due to sanctions. Liquidity ensures the company's stability amidst the disruption of global logistics chains.